PATENT CLAIM ANALYSIS

Application Number: 16040324
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "081000"]

Abstract:
The disclosure is directed to methods of treating subjects infected with HIV, once daily, with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and a tenofovir prodrug, or salt thereof.

Claim (Index 29):
The single unit dosage form of  claim 25 , wherein the single unit dosage form comprises about 10 mg of tenofovir alafenamide.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 95.0
- Lexical Diversity: 1.27778
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15913750', '14679887', '11669547', '15406344', '14747621']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7970335215864539
- 35 USC 102 Novelty (BERT): 0.5187718914222419
- Combined Prediction Score: 0.7692073585700328
- Mean Citation Score: 309.5180220000001
- Max Citation Score: 312.86664
- Similarity Product: 230.10274002699853

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test